Pathophysiology of dyslipidemia in Cushing's syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing mechanistic pathways without systematic review methodology or primary clinical data.
PubMed 20829625 · doi:10.1159/000314213
What was done
The authors reviewed published literature on the pathophysiological mechanisms causing dyslipidemia in overt and subclinical Cushing's syndrome, focusing on direct and indirect glucocorticoid actions across adipose tissue, liver, and peripheral signaling pathways.
What was found
Cushing's syndrome is marked by increases in triglyceride and total cholesterol levels with variable HDL levels. Cortisol promotes lipoprotein lipase and lipolysis in visceral fat, increasing circulating free fatty acids and reducing hepatic insulin signaling. Preclinical studies demonstrated that liver-specific disruption of glucocorticoid receptors reduces hepatic triglyceride accumulation. In human data cited in the abstract, up to 20% of patients with Cushing's syndrome present with hepatic steatosis.
Why it matters
Understanding the multi-pathway drivers of dyslipidemia in hypercortisolemia helps explain the shared features between Cushing's syndrome and metabolic syndrome that elevate overall cardiovascular risk.
Limits
As a narrative review, it lacks systematic search methodology, quality assessment, and pooled quantitative effect estimates. Much of the detailed pathway data relies on in vitro and animal models rather than controlled human clinical trials.
Cited by
- supports Elevated stress hormones mobilize glucose and lipids into the bloodstream which, if unused by tissues, deposit as ectopic visceral adipose tissue.